Zydus Lifesciences Limited (ZYDUSLIFE) announced today a significant milestone in its U.S. operations by launching the first generic version of Adempas® (riociguat) in partnership with MSN Laboratories Private Limited (MSN). This launch marks the first-to-market availability of riociguat tablets in the U.S., offering a lower-cost alternative to patients suffering from pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

First-to-Market Launch

The riociguat tablets, available in five strengths (0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg), are now approved by the United States Food and Drug Administration (USFDA) as a generic equivalent of Adempas® tablets. This development is a testament to the strength of Zydus’ complex-generics pipeline and its ability to execute day-one launches in specialty categories.

Impact on Patients

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Limited, emphasized the importance of this launch, stating, ‘Being first to market with generic riociguat is a milestone for our U.S. business and for patients with pulmonary hypertension.’ Riociguat is a soluble guanylate cyclase (sGC) stimulator that helps improve exercise capacity and functional class for patients with PAH and CTEPH, conditions that are rare, progressive, and life-threatening. This launch ensures that more patients can access this critical therapy at a reduced cost.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zydus Lifesciences Limited

Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.69 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock gains 1.7% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.

Sai Parenterals Limited (NSE: SAIPARENT) has completed the acquisition of a 60% equity stake in Prathyak Laboratories Private Limited for Rs. 15 crore, funded from the unutilised net proceeds of the Company’s initial public offering. This acquisition replaces the greenfield research centre the Company had originally intended to build. Prathyak Laboratories, now renamed as Sai Prathyak Laboratories Private Limited, has been in operation for three years and brings 28 research scientists and a development pipeline of 150 SKUs across 86 molecules. The acquisition provides Sai Parenterals with immediate access to a fully operational R&D facility, significantly accelerating its development work and reducing the time and effort required to assemble a scientific team.

Strategic Benefits of the Acquisition

The acquisition of an operating R&D platform rather than constructing one allows development work to begin immediately. It removes the construction cycle and, more significantly, the considerably harder task of assembling a scientific team of this calibre, which would have slowed the pace of a greenfield build. Prathyak’s development work supports the Company’s injectable programme directly. Formulations developed at this R&D centre can be taken into commercial production as the Company’s injectable capacity is expanded and upgraded, shortening the path from development to supply in regulated and semi-regulated markets.

Future Plans and Expansion

The residual 40% may be acquired through a Right of First Refusal (ROFR) at the same valuation as the present transaction, to be funded from internal accruals, taking Prathyak to a wholly owned position. Commenting on the acquisition, Mr. Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, said: ‘Building a research centre from the ground up would have cost us a construction cycle and, far more significantly, the time taken to assemble a scientific team. Prathyak gives us both on day one — 28 research scientists who have worked together for three years, and a pipeline of 150 SKUs across 86 molecules in exactly the complex injectable and oncology areas we are building towards. The value of this acquisition lies in what it enables elsewhere in the Group. Work already completed at this R&D centre can be taken into production as our injectable capacity is expanded. The same R&D team will also develop the new products we are required to launch each year under our Australian agreements. We have acquired 60% today and will move to full ownership at the same valuation. This is a further step in the growth plan we set out at the time of our listing: deeper integration across our own value chain, a faster route from development to commercial supply, and capability built inside the Group instead of with third parties. We will continue to pursue opportunities of this kind, organic and inorganic, that strengthen the platform and create lasting value for our stakeholders.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Parenterals Limited

Sai Parenterals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Sai falls 15.3% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 126.1% and profits at 111.8% CAGR. Both numbers are exceptional. The stock gains 0.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Both the business and the stock move in the right direction. Revenue grows at 126.1%, profits at 111.8%, and the PEG sits at 0.99 — below its growth rate. That combination is rare. Check Fundamentals of Sai Parenterals Limited.

Aurobindo Pharma Limited (NSE: AUROPHARMA) is pleased to announce the receipt of final approval from the US Food & Drug Administration (USFDA) to manufacture and market Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. These tablets are bioequivalent and therapeutically equivalent to the reference listed drug, Fycompa® Tablets, of Catalyst Pharmaceuticals, Inc. The product will be manufactured at Unit -IV of APL Healthcare, a wholly-owned subsidiary of the Company, and is set to launch in Q3FY27. The approved product has an estimated market size of US$ 67 million for the twelve months ending August 2026, according to IQVIA MAT.

Significance of Approval

This approval marks a significant milestone for Aurobindo Pharma as it expands its portfolio of CNS products. Perampanel Tablets are indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 4 years and older and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older.

Company’s Growth and Future Prospects

With this approval, Aurobindo Pharma now has a total of 599 ANDA approvals from USFDA. The company continues to strengthen its position in the global pharmaceutical market with its robust product portfolio spread over seven major therapeutic areas. Aurobindo Pharma’s commitment to innovation and quality is evident in its extensive list of manufacturing and packaging facilities approved by leading regulatory agencies worldwide.

Aurobindo Pharma Limited remains dedicated to its mission of delivering high-quality, affordable medications to patients globally. With the launch of Perampanel Tablets, the company is poised to further its growth and contribute to improved patient outcomes in the epilepsy treatment landscape.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Aurobindo Pharma Limited

Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Aurobindo posts a 3.5% three-month gain, but softens in the last few weeks. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 0.4% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.17 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.